ABT-333

DRUG18 trials

Sponsors

AbbVie, AbbVie (prior sponsor, Abbott), Abbott

Conditions

Chronic Hepatitis CChronic Hepatitis C InfectionChronic Hepatitis C Virus (HCV)Chronic Hepatitis C Virus (HCV) Infection Genotype 1Chronic Hepatitis C Virus InfectionCompensated Cirrhosis and Non-cirrhoticsHCVHCV Infection

Phase 1

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

CompletedNCT00696904

AbbVieHCV Infection

Start: 2008-06-30Updated: 2017-11-21

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

CompletedNCT00768690

AbbottHCV Infection

Start: 2008-10-31Updated: 2010-10-13

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

CompletedNCT00909636

AbbottHCV Infection

Start: 2009-05-31Updated: 2010-10-13

A Study of Single Dose of ABT-333 in Healthy Male Adults

CompletedNCT00919490

AbbottHCV Infections

Start: 2009-06-30Updated: 2010-10-25

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

CompletedNCT02052349

AbbVieRelative Bioavailability

Start: 2013-11-30End: 2013-12-31Updated: 2014-02-03

Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

CompletedNCT02534870

AbbVieHealthy Volunteer

Start: 2015-09-30End: 2015-09-30Updated: 2015-10-19

Phase 2

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

CompletedNCT00726882

AbbVie (prior sponsor, Abbott)HCV Infection

Start: 2008-08-31End: 2010-05-31Updated: 2015-01-08

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

CompletedNCT00851890

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Virus Infection

Start: 2009-03-31End: 2009-07-31Updated: 2018-07-02

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

CompletedNCT01074008

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection, HCV, Hepatitis C +1

Start: 2010-03-31End: 2012-01-31Updated: 2015-01-08

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

CompletedNCT01306617

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus

Start: 2011-02-28End: 2012-10-31Updated: 2015-01-08

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

CompletedNCT01464827

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C, Hepatitis C Genotype 1, Hepatitis C (HCV)

Start: 2011-10-31End: 2013-09-30Updated: 2015-04-22

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

CompletedNCT01563536

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection

Start: 2012-02-29End: 2013-06-30Updated: 2018-07-02

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

CompletedNCT01911845

AbbVieChronic Hepatitis C, Chronic Hepatitis C Infection

Start: 2013-04-30End: 2014-09-30Updated: 2018-05-30

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

CompletedNCT01939197

AbbVieChronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics, Hepatitis C Virus Infection +1

Start: 2013-08-30End: 2016-10-25Updated: 2021-07-12

Phase 3

A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

CompletedNCT01773070

AbbVie (prior sponsor, Abbott)Hepatitis C

Start: 2013-06-30End: 2016-10-31Updated: 2017-12-06

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

CompletedNCT02167945

AbbVieChronic Hepatitis C Virus (HCV) Infection Genotype 1

Start: 2014-06-12End: 2021-05-13Updated: 2022-07-19

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

CompletedNCT02219490

AbbVieChronic Hepatitis C Virus (HCV) Infection Genotype 1

Start: 2014-10-30End: 2021-05-13Updated: 2023-04-07

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

CompletedNCT02517528

AbbVieChronic Hepatitis C Virus (HCV)

Start: 2015-07-20End: 2017-03-16Updated: 2018-10-09

Related Papers

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.

2019-02-012 citations

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

2017-04-13213 citations

Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses

Antimicrobial Agents and Chemotherapy2016-12-063 citations

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?

2016-01-0661 citations

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir

Antimicrobial Agents and Chemotherapy2015-06-2395 citations

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

JAMA2015-02-23305 citations

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450

Antimicrobial Agents and Chemotherapy2014-12-02116 citations

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

New England Journal of Medicine2014-01-15256 citations

Exploratory study of oral combination antiviral therapy for hepatitis C.

2013-01-01225 citations